Search

•Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL) for oligometastatic disease.•We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.•In this work a large variation in treatment strategies was found. Since currently there is little evidence preferring one strategy over the other, clinical registries and future research need to focus on the clinical relevance of the variations in institutional treatment strategies.

Pre-operative radiotherapy (RT) followed by limb-sparing resection is commonly used to treat soft tissue sarcomas (STS) of the extremity and chest-wall; however, this is associated with an increased risk of post-operative wound complications (WCs) compared to adjuvant RT. The use of intensity-modulated radiotherapy (IMRT) in STS has been investigated; however, the impact on WC is sparsely reported. In this study, we assess the rates of WC in patients who underwent pre-operative 3D conformal RT (3D CRT) versus IMRT followed by surgery for STS. From 2000 to 2012, 196 patients with localized STS were treated with RT +/− chemotherapy followed by resection. Patient, treatment variables, and outcomes were reviewed. Predictors for WC were evaluated using Fisher’s exact test for univariate analysis (UVA) and logistic regression for multivariate analysis (MVA). Median follow-up was 3.5 years. Of patients, 33.7 % were treated with IMRT and 66.3 % were treated with 3D CRT. Of patients, 28.6 % developed post-operative WCs. Eighteen percent of patients developed WCs when treated with IMRT versus 33 % who received 3D CRT (p= 0.03). In lower extremity tumors only, 20 % of patients that received IMRT and 43 % of patients that received 3D CRT patients had WC (p= 0.01). On MVA, both upper extremity STS (p= 0.0005, OR 0.14) and IMRT (p= 0.02, OR 0.40) predicted for a decreased propensity for post-operative WC. IMRT was associated with a significantly decreased risk of post-operative WCs compared to patients who received 3D CRT for their STS. Further studies and a larger sample size are needed to corroborate these findings.

Recent reports state that the prevalence of tardive dyskinesia (TD) is 32% with typical antipsychotics, and 13% with atypical antipsychotics. Current evidence-based recommendations determine an unmet need for efficacious treatment of TD. This systematic review was planned to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine (DBZ), and valbenazine (VBZ). Of 75 PubMed search results, 11 studies met the review criteria. Efficacy and tolerability were demonstrated in a series of randomized, placebo-controlled clinical trials in our review study, and the Abnormal Involuntary Movement Scale response of ⩾50% reduction in score was robust for VBZ 80 mg/day in short-term and long-term studies. On the contrary, DBZ was equally efficacious at 12 mg twice daily, but additional information about long-term efficacy and persistence of effect is needed.